Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | JAK2 R683G JAK2 L884P |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| JAK2 R683G JAK2 L884P | Advanced Solid Tumor | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited viability of a cell line expressing JAK2 R683G and L884P in culture (PMID: 37290440). | 37290440 | |
| JAK2 R683G JAK2 L884P | Advanced Solid Tumor | sensitive | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Inrebic (fedratinib) inhibited viability of a cell line expressing JAK2 R683G and L884P in culture (PMID: 37290440). | 37290440 | |
| JAK2 R683G JAK2 L884P | Advanced Solid Tumor | resistant | CHZ868 | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line expressing JAK2 R683G and L884P was resistant to CHZ868 in culture (PMID: 37290440). | 37290440 | |
| JAK2 R683G JAK2 L884P | hematologic cancer | resistant | CHZ868 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing JAK2 R683G and L884P were resistant to CHZ868 in culture (PMID: 26175414). | 26175414 |